CG Oncology is an oncolytic immunotherapy company that is intensely focused on developing bladder saving therapeutics for patients with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative therapies to live and work with dignity and an enhanced quality of life.

Cretostimogene grenadenorepvec

is a targeted oncolytic immunotherapy agent that has shown remarkable efficacy in bladder cancer.

CG Oncology by the Numbers

Active clinical programs

with planned studies soon underway. See current clinical trials.


Complete response rate

at any time for CG0070 in combination with KEYTRUDA®


Complete response rate

at 12 months for CG0070 in combination with KEYTRUDA®


Latest News